UK markets closed

Titan Pharmaceuticals, Inc. (TTNP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.97-0.08 (-1.06%)
As of 12:47PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 6.37M
Enterprise value 178.21k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.24k
Price/book (mrq)0.96
Enterprise value/revenue 178.21
Enterprise value/EBITDA -0.02

Trading information

Stock price history

Beta (5Y monthly) 1.35
52-week change 3-55.32%
S&P500 52-week change 321.08%
52-week high 316.60
52-week low 35.00
50-day moving average 37.32
200-day moving average 38.15

Share statistics

Avg vol (3-month) 310.78k
Avg vol (10-day) 32.18k
Shares outstanding 5914.23k
Implied shares outstanding 6914.23k
Float 8699.98k
% held by insiders 145.47%
% held by institutions 15.52%
Shares short (15 Apr 2024) 410.18k
Short ratio (15 Apr 2024) 40.67
Short % of float (15 Apr 2024) 41.37%
Short % of shares outstanding (15 Apr 2024) 41.11%
Shares short (prior month 15 Mar 2024) 412.04k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 301 Dec 2020
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 309 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-3,954.89%

Management effectiveness

Return on assets (ttm)-74.90%
Return on equity (ttm)-139.14%

Income statement

Revenue (ttm)184k
Revenue per share (ttm)0.25
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -7.17M
Net income avi to common (ttm)-5.57M
Diluted EPS (ttm)-7.41
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)6.76M
Total cash per share (mrq)7.39
Total debt (mrq)565k
Total debt/equity (mrq)8.51%
Current ratio (mrq)5.55
Book value per share (mrq)8.50

Cash flow statement

Operating cash flow (ttm)-7.09M
Levered free cash flow (ttm)-5.65M